Immunoprecise(IPA) - 2023 Q2 - Earnings Call Transcript

Financial Data and Key Metrics Changes - ImmunoPrecise Antibodies Ltd. recorded total revenue of $5.2 million during Q2 2023, a 9.8% increase from $4.7 million in Q2 2022 [39] - Gross profit for the quarter totaled $2.8 million, a 7.9% increase compared to the same period last year, with a gross profit margin of 54%, slightly down from 55% in fiscal 2022 [40] - The company reported a net loss of $7.4 million during Q2 2023, compared to a net loss of $5 million during the same period last year, primarily due to increased investment in R&D and higher G&A costs [47] Business Line Data and Key Metrics Changes - The sales team expanded in key geographic areas, contributing to a 9.8% increase in revenue, with record quarters at both the Canadian and Utrecht sites [19] - The Canadian site reported a single monthly revenue record of over $844,000 in October [19] - BioStrand's integration into the company's offerings is expected to enhance revenue recognition and profit margins due to quicker turnaround times for in silico services [13] Market Data and Key Metrics Changes - The global organoids market is valued at over $2 billion in 2021 and is predicted to reach over $12 million by 2030, with a CAGR of 21.58% [22] - The company has seen an uptick in Wnt surrogate production and sales, indicating a growing demand for growth factors in the organoids market [22] Company Strategy and Development Direction - The company announced its voluntary delisting from the TSX Venture to create a central market for its shares on NASDAQ, enhancing long-term liquidity and shareholder value [7] - The focus is on accelerated revenue growth and sales integration of in silico capabilities, with expectations of doubling revenue from the expanded facility in Utrecht [9][55] - The strategic collaboration with BriaCell marks a shift towards non-fee-for-service based discovery programs, indicating a new business model for BioStrand [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to outperform current market conditions and achieve significant growth [11] - The integration of AI-driven platforms into drug discovery is expected to save development time and costs, enhancing the company's competitive edge [12] - The management is confident in the sustainability of the PolyTope program's efficacy against emerging SARS-CoV-2 variants, positioning the company favorably in the market [72] Other Important Information - The company has received promising feedback regarding its U.S. national patents for PolyTope, with expectations of granting being close [32] - The transition to a new accelerator facility in Utrecht has doubled lab space and increased production capacity, leading to revenue gains from new service offerings [35] Q&A Session Summary Question: Revenue trajectory and growth expectations from European resources - Management highlighted the expansion in Utrecht as ROI-generating space, anticipating significant revenue growth from high-throughput and large-scale manufacturing opportunities [52][55] Question: Timeline for AI-based product offerings and growth expectations - Management indicated that expected timelines for in silico work outputs are about four weeks, with revenue generation anticipated within eight to ten weeks after program initiation [60][64] Question: Wnt protein sales and market expectations - Management clarified that the decrease in product sales is not directly related to Wnt protein, and they expect it to capture a larger market share due to its quality and stability [66][69] Question: Commercial opportunity for PolyTope and oncology offerings - Management expressed confidence in PolyTope's sustained efficacy and its potential market position, while indicating that oncology programs are intended for out-licensing rather than clinical trials [72][82] Question: Differentiation of BioStrand technology - Management noted that the unique HYFT technology and LENSai software are key differentiators that resonate with potential partners, driving excitement in discussions [98][100]